Pfizer Reports P-III Trial Results of Pentavalent Meningococcal Vaccine (MenABCWY) for Invasive Meningococcal Disease
Shots:
- The P-III trial evaluated MenABCWY in 2431 healthy adolescents & young adults aged 10 through 25yrs. with IMD across US & EU
- The trial met 1EPs & 2EPs i.e., the vaccine was well-tolerated with an acceptable safety profile, and immunogenicity was non-inferior to licensed vaccines (2 doses of Trumenba & 1 dose of Menveo) for 5 meningococcal serogroups
- A single dose of MenABCWY met the non-inferiority criteria over 1 dose of Menveo, patients who received 2 doses of MenABCWY showed greater immune responses with ≥4-fold increases against 4 serogroup B viruses over licensed vaccines. The company plans to submit an application to the US FDA for approval of the vaccine in Q4’22 7 & is also being planned outside the US
Ref: Businesswire | Image: Pfizer
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
